{"id":"MSKCC_Motzer.v0.0.8","gdl_version":"2.0","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Shweta Prasad Ghaisas","email":"s.prasad.ghaisas@cambio.se","organisation":"Cambio CDS","date":"2025-02-13"},"lifecycle_state":"Author draft","details":{"en":{"id":"en","copyright":"© Cambio CDS","keywords":["renal cell carcinoma","renal cell cancer","carcinoma","cancer","metastatic renal cell carcinoma","metastatic carcinoma","hemoglobin","calcium","Memorial Sloan-Kettering Cancer Center","Motzer score","LDH","l-lactate dehydrogenase","performance status","time from diagnosis to systemic treatment"],"purpose":"To calculate and interpret the total sum for the MSKCC/Motzer score.","use":"The guideline is used to calculate the Total score and/or the interpretation of the calculated Total score in the form of \"risk group\" and \"median survival 4 months\" in patients with metastatic renal cell carcinoma undergoing systemic therapy. It can be used to identify patients being considered for clinical trial enrollment, and in clinical practice for the estimation of prognosis. The risk here refers to the risk to survival. The Total score is stratified for risk and median survival as follows:\n\n1. Score: 0, Risk: Good, Median survival: 20 months\n\n2. Score: 1-2, Risk: Intermediate, Median survival: 10 months\n\n3. Score: ≥3, Risk: High, Median survival: 4 months","misuse":"Not to be used for making decisions about treatment for metastatic renal cell carcinoma."}},"other_details":{"en":"An assessment score to predict survival based on clinical and laboratory data in metastatic renal cell carcinoma patients.","references":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40.\n\nMotzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96.\n\nMotzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454-63.\n\nMotzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90."},"other_contributors":[]},"definition":{"data_bindings":{"gt0002":{"id":"gt0002","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.mskcc_motzer.v0","template_id":"openEHR-EHR-OBSERVATION.mskcc_motzer.v0","elements":{"gt0003":{"id":"gt0003","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"},"gt0004":{"id":"gt0004","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0007]"},"gt0005":{"id":"gt0005","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0010]"},"gt0006":{"id":"gt0006","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]"},"gt0007":{"id":"gt0007","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0016]"}}},"gt0008":{"id":"gt0008","type":"OUTPUT","model_id":"openEHR-EHR-EVALUATION.mskcc_motzer_assessment.v0","template_id":"openEHR-EHR-EVALUATION.mskcc_motzer_assessment.v0","elements":{"gt0010":{"id":"gt0010","path":"/data[at0001]/items[at0003]"}}},"gt0011":{"id":"gt0011","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.mskcc_motzer.v0","template_id":"openEHR-EHR-OBSERVATION.mskcc_motzer.v0","elements":{"gt0012":{"id":"gt0012","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0019]"}}},"gt0017":{"id":"gt0017","type":"OUTPUT","model_id":"openEHR-EHR-EVALUATION.health_risk_Motzer.v1","template_id":"openEHR-EHR-EVALUATION.health_risk_Motzer.v1","elements":{"gt0018":{"id":"gt0018","path":"/data[at0001]/items[at0002]"}}}},"templates":{},"rules":{"gt0013":{"id":"gt0013","priority":4,"then":["$gt0012|Total score| = $gt0003|Time from diagnosis to systemic treatment <1 year|.value + $gt0004|Hemoglobin < Lower Limit of Normal|.value + $gt0005|Calcium >10mg/dL (>2.5 mmol/L)|.value + $gt0006|LDH > 1.5x Upper Limit of Normal|.value + $gt0007|Performance status <80% (Karnofsky)|.value"],"when":["$gt0003|Time from diagnosis to systemic treatment <1 year| != null","$gt0004|Hemoglobin < Lower Limit of Normal| != null","$gt0005|Calcium >10mg/dL (>2.5 mmol/L)| != null","$gt0006|LDH > 1.5x Upper Limit of Normal| != null","$gt0007|Performance status <80% (Karnofsky)| != null"],"description":"The rule adds individual scores of all input fields to give a total score."},"gt0014":{"id":"gt0014","priority":3,"then":["$gt0010|Median survival (months)| = 20","$gt0018|Health risk| = local::at0031|Good|"],"when":["$gt0012|Total score| == 0"]},"gt0015":{"id":"gt0015","priority":2,"then":["$gt0010|Median survival (months)| = 10","$gt0018|Health risk| = local::at0032|Intermediate|"],"when":["$gt0012|Total score| >= 1","$gt0012|Total score| <= 2"]},"gt0016":{"id":"gt0016","priority":1,"then":["$gt0010|Median survival (months)| = 4","$gt0018|Health risk| = local::at0033|High|"],"when":["$gt0012|Total score| >= 3"]}}},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"id":"gt0001","text":"MSKCC/Motzer score for metastatic renal cell carcinoma","description":"An assessment score to predict survival based on clinical and laboratory data in metastatic renal cell carcinoma patients."},"gt0002":{"id":"gt0002","text":"openEHR-EHR-OBSERVATION.mskcc_motzer.v0"},"gt0003":{"text":"Time from diagnosis to systemic treatment <1 year","description":"This is one of the input values for the total score and refers to time from diagnosis to systemic treatment, it is measured ~1 month after stopping anticoagulation.","id":"gt0003"},"gt0004":{"text":"Hemoglobin < Lower Limit of Normal","description":"An input field that asks for serum hemoglobin concentration where the normal values are defined as:\n\nMen (Normal): 13.5-17.5 g/dL\nWomen (Normal): 12.0-15.5 g/dL","id":"gt0004"},"gt0005":{"text":"Calcium >10mg/dL (>2.5 mmol/L)","description":"An input field that asks for serum calcium concentration.","id":"gt0005"},"gt0006":{"text":"LDH > 1.5x Upper Limit of Normal","description":"Here the normal concentration is given as: Normal: 140 U/L. The input field asks for serum LDH concentration.","id":"gt0006"},"gt0007":{"id":"gt0007","text":"Performance status <80% (Karnofsky)"},"gt0008":{"id":"gt0008","text":"openEHR-EHR-EVALUATION.mskcc_motzer_assessment.v0"},"gt0010":{"text":"Median survival (months)","description":"Estimation of survival of the patient for the next 4 months.","id":"gt0010"},"gt0011":{"id":"gt0011","text":"openEHR-EHR-OBSERVATION.mskcc_motzer.v0"},"gt0012":{"text":"Total score","description":"The rule adds individual scores of all input fields to give a total score.","id":"gt0012"},"gt0013":{"text":"Total score","description":"The rule adds individual scores of all input fields to give a total score.","id":"gt0013"},"gt0014":{"text":"Risk_Good","description":"When the total score is 0, the risk is good or favourable.","id":"gt0014"},"gt0015":{"text":"Risk_Intermediate","description":"When the total score is 1 or 2, the risk is intermediate.","id":"gt0015"},"gt0016":{"text":"Risk_High","description":"When the total score is 3 or more, the risk to survival is high.","id":"gt0016"},"gt0017":{"id":"gt0017","text":"openEHR-EHR-EVALUATION.health_risk_Motzer.v1"},"gt0018":{"text":"Health risk","description":"This forms a part of the interpretation of Total score and gives the risk to survival of the patient with metastatic renal cell carcinoma.","id":"gt0018"}}}},"term_bindings":{}}}